Navigation Links
PharmAthene Reports Third Quarter 2013 Financial And Operational Results
Date:11/7/2013

he third quarter of 2012. The increase in general and administrative expenses in the third quarter of 2013 was due primarily to an increase in merger-related transaction costs.

Net LossFor the third quarter of 2013, PharmAthene's net loss was $3.9 million, or $0.08 per share, compared to a net loss of $0.2 million, or $0.00 per share during the same period in 2012.  The increase in net loss is primarily due to:  a change in the fair value of the Company's derivative instruments, which was largely the result of the change in the closing market price of PharmAthene's common stock; the 2012 gain on the realization of cumulative translation adjustment; and an increase in merger-related transaction costs in the 2013 period.

Cash, Cash Equivalents and Accounts ReceivableAs of September 30, 2013, the Company had cash and cash equivalents totaling approximately $15.9 million, compared to $12.7 million as of December 31, 2012.  U.S. government billed and unbilled accounts receivable totaled approximately $1.6 million at September 30, 2013 compared to $6.5 million at December 31, 2012.  The sum total of cash and cash equivalents and U.S. government accounts receivable at September 30, 2013 was approximately $17.6 million, compared to $19.2 million as of December 31, 2012.

About PharmAthenePharmAthene is a leading biodefense company engaged in the development and commercialization of next generation medical countermeasures against biological and chemical threats. PharmAthene's current biodefense portfolio includes the following product candidates:

  • SparVax® - a next generation recombinant protective (rPA) anthrax vaccine
  • rBChE bioscavenger - a medical countermeasure for nerve agent poisoning by organophosphorous compounds, including nerve gases and pesticides
  • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • In addition
    '/>"/>

    SOURCE PharmAthene, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. PharmAthene to Present at Rodman & Renshaw Annual Global Investment Conference
    2. PharmAthene and Theraclone Sciences Announce Merger Agreement to Create Diversified Biologics Company Targeting Government and Commercial Markets
    3. PharmAthene Reports First Quarter 2013 Financial And Operational Results
    4. New Data Show PharmAthenes Recombinant Bioscavenger Binds To A Broad Spectrum Of Chemical Nerve Agents
    5. SIGA Technologies Files Notice of Appeal in PharmAthene Litigation
    6. Pharmacyclics Reports Third Quarter 2013 Results
    7. CareFusion Reports First Quarter Fiscal 2014 Results
    8. Sequenom, Inc. Reports Financial Results For The Third Quarter Of 2013
    9. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results
    10. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
    11. ANI Pharmaceuticals Reports Net Revenues of $7.8 million, adjusted Non-GAAP EBITDA of $1.7 Million, and EPS of $0.13 for the Third Quarter Ended September 30, 2013
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/3/2015)... , August 3, 2015 ... announced today that it has acquired ... Inc. for $300 million. With the acquisition, Shire ... drops combining 0.6% povidone iodine (PVP-I) and 0.1% ... treatment of infectious conjunctivitis, an ocular surface condition ...
    (Date:7/31/2015)... CHAPEL HILL, N.C. , July 31, 2015 ... to product success in the biopharmaceutical market. Patients ... the process of selecting and switching therapies. This ... and is pushing marketers, efforts toward patient-focused marketing. ... to patient engagement, marketers have learned it,s important ...
    (Date:7/31/2015)... 31, 2015 RnRMarketResearch.com adds ... research report that provides an overview of syringes ... sourced from in-house databases, secondary and primary research. ... market products pipeline spread across 124 pages, talking ... tables and 5 figures is now available at ...
    Breaking Medicine Technology:Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 2Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 3Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 4Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 5Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 6Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
    ... Calif., Jan. 4, 2011 Intarcia Therapeutics, Inc. today ... will present at the 29th Annual JP Morgan Healthcare ... 2011 at the Westin St. Francis Hotel in San ... About Intarcia Intarcia Therapeutics, ...
    ... Pa., Jan. 4, 2011 Owner and medical director of ... her practice and is now offering Pixel Perfect™ ... CO2 laser from Alma Lasers. "I,m very ... Cirillo-Hyland said. "As a long time provider of aesthetic laser ...
    Cached Medicine Technology:Intarcia Therapeutics Executive Chairman Kurt Graves to Present at 29th Annual JP Morgan Healthcare Conference 2Philadelphia's Victoria A. Cirillo-Hyland, M.D. Adds Alma Lasers' Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients 2
    (Date:8/3/2015)... ... August 03, 2015 , ... Sensato and ... “Designing Secure Healthcare Systems” This three-day, highly interactive and immersive workshop, has ... with access to the tactics, techniques and practices required to design and develop ...
    (Date:8/3/2015)... ... , ... A July 13 article from The Daily Mail titled "Jab ... That Can Last 'For Five Weeks'" discusses the use of stem cells to ... that harvesting stem cell-rich bone marrow from the hip, known as bone marrow stromal ...
    (Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... ... global insurance brokerage firm, announced today that Joe Williams has joined its growing ... sales, and delivering HUB's differentiated service model to his clients. Mr. Williams will ...
    (Date:8/3/2015)... ... August 03, 2015 , ... Examination ... and investigative services, has introduced a new logo and comprehensive brand strategy ... improve business outcomes for its customers. EMSI’s new tagline, “Powerful Information. Improved ...
    (Date:8/2/2015)... ... August 03, 2015 , ... Career Step, an online institution ... Association for Healthcare Documentation Integrity’s (AHDI) conference being held in Alexandria, Virginia, on ... the AHDI conference provides us to interact with those in the healthcare documentation ...
    Breaking Medicine News(10 mins):Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2
    ... -- The death rate among children with severe malaria was ... artesunate than when they got the standard treatment of quinine, ... should replace quinine as the malaria treatment of choice for ... that is transmitted via the bite of an infected mosquito, ...
    ... 2010 Approximately 600,000 hysterectomies are performed in ... of the pelvis. More than two-thirds are performed ... statement published online today in The Journal ... medical specialty society of over 5,000 gynecologic surgeons, ...
    ... Thompson HealthDay Reporter , FRIDAY, Nov. 5 (HealthDay ... to rest as much as possible and avoid exertion, to ... But a growing number of physicians and researchers now say ... during treatment are more likely to beat cancer. The ...
    ... News) -- An international consortium of researchers has linked a ... increased risk for both autism spectrum disorders (ASD) and schizophrenia. ... an important role in the risk of both disorders, this ... specific abnormality, which takes the form of a wholesale absence ...
    ... This release is also available in Chinese on ... Thousands of the world,s top scientists and clinicians in the ... at the American Society of Human Genetics 60th Annual Meeting, which ... A number of scientific presentations at this year,s meeting will feature ...
    ... , FRIDAY, Nov. 5 (HealthDay News) -- New ... those who carry a particular gene mutation are particularly ... The apparent link between a specific variation of the ... is the first hard evidence to suggest that there ...
    Cached Medicine News:Health News:New Malaria Drug Proves Effective in Study of African Children 2Health News:Most hysterectomies should be performed vaginally or laparoscopically 2Health News:To Best Fight Cancer, New Guidelines Urge Exercise 2Health News:To Best Fight Cancer, New Guidelines Urge Exercise 3Health News:To Best Fight Cancer, New Guidelines Urge Exercise 4Health News:Genetic Deletion Linked to Raised Risk of Autism, Schizophrenia 2Health News:Studies validate use of family health history as gold standard in disease risk assessment 2Health News:Studies validate use of family health history as gold standard in disease risk assessment 3Health News:Studies validate use of family health history as gold standard in disease risk assessment 4Health News:Studies validate use of family health history as gold standard in disease risk assessment 5Health News:Studies validate use of family health history as gold standard in disease risk assessment 6Health News:Studies validate use of family health history as gold standard in disease risk assessment 7Health News:Studies validate use of family health history as gold standard in disease risk assessment 8Health News:Studies validate use of family health history as gold standard in disease risk assessment 9Health News:Studies validate use of family health history as gold standard in disease risk assessment 10Health News:Studies validate use of family health history as gold standard in disease risk assessment 11Health News:Research Suggests Link Between 'Handedness' and Dyslexia 2
    Extremely fine straight....
    Curved delicate 5 mm blades....
    Micro dressing forceps....
    ... The Leica M520 OH3 is ... best optical performance available on ... and unique stand. The Leica ... has the greatest range of ...
    Medicine Products: